First assessment of thermoacoustic tomography for in vivo detection of rheumatoid arthritis in the finger joints

2021 ◽  
Author(s):  
Zihui Chi ◽  
Lin Huang ◽  
Dan Wu ◽  
Xiaojun Long ◽  
Xueliang Xu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Thermoacoustic Tomography ◽  
Finger Joints ◽  
In Vivo Detection

scholarly journals First assessment of three-dimensional quantitative photoacoustic tomography for in vivo detection of osteoarthritis in the finger joints

2011 ◽  
Vol 38 (7) ◽  
pp. 4009-4017 ◽  
Author(s):  
Yao Sun ◽  
Eric S. Sobel ◽  
Huabei Jiang
Keyword(s):  
Three Dimensional ◽  
Photoacoustic Tomography ◽  
Finger Joints ◽  
In Vivo Detection

Technical Note: Anti‐phase microwave illumination‐based thermoacoustic tomography of in vivo human finger joints

2019 ◽  
Vol 46 (5) ◽  
pp. 2363-2369 ◽  
Author(s):  
Zihui Chi ◽  
Lin Huang ◽  
Shaoli Ge ◽  
Huabei Jiang
Keyword(s):  
Technical Note ◽  
Thermoacoustic Tomography ◽  
Finger Joints ◽  
Human Finger

In vivo detection and imaging of low-density foreign body with microwave-induced thermoacoustic tomography

2009 ◽  
Vol 36 (8) ◽  
pp. 3429-3437 ◽  
Author(s):  
Liming Nie ◽  
Da Xing ◽  
Sihua Yang
Keyword(s):  
Foreign Body ◽  
Low Density ◽  
Thermoacoustic Tomography ◽  
In Vivo Detection

Thermoacoustic Tomography of In Vivo Human Finger Joints

2019 ◽  
Vol 66 (6) ◽  
pp. 1598-1608 ◽  
Author(s):  
Zihui Chi ◽  
Yuan Zhao ◽  
Jinge Yang ◽  
Tingting Li ◽  
Guang Zhang ◽  
...  
Keyword(s):  
Thermoacoustic Tomography ◽  
Finger Joints ◽  
Human Finger

Effects of a Monoclonal Antibody to Glycoprotein IIb/IIIa (P256) and of Enzymically Derived Fragments of P256 on Human Platelets

1991 ◽  
Vol 65 (04) ◽  
pp. 432-437 ◽  
Author(s):  
A W J Stuttle ◽  
M J Powling ◽  
J M Ritter ◽  
R M Hardisty
Keyword(s):  
Monoclonal Antibody ◽  
Flow Cytometry ◽  
Platelet Aggregation ◽  
Calcium Ions ◽  
Human Platelet ◽  
Human Platelets ◽  
In Vivo Detection ◽  
Fibrinogen Binding ◽  
Specific Antagonist

SummaryThe anti-platelet monoclonal antibody P256 is currently undergoing development for in vivo detection of thrombus. We have examined the actions of P256 and two fragments on human platelet function. P256, and its divalent fragment, caused aggregation at concentrations of 10−9−3 × 10−8 M. A monovalent fragment of P256 did not cause aggregation at concentrations up to 10−7 M. P256–induced platelet aggregation was dependent upon extracellular calcium ions as assessed by quin2 fluorescence. Indomethacin partially inhibited platelet aggregation and completely inhibited intracellular calcium mobilisation. Apyrase caused partial inhibition of aggregation. Aggregation induced by the divalent fragment was dependent upon fibrinogen and was inhibited by prostacyclin. Aggregation induced by the whole antibody was only partially dependent upon fibrinogen, but was also inhibited by prostacyclin. P256 whole antibody was shown, by flow cytometry, to induce fibrinogen binding to indomethacin treated platelets. Monovalent P256 was shown to be a specific antagonist for aggregation induced by the divalent forms. In–111–labelled monovalent fragment bound to gel-filtered platelets in a saturable and displaceable manner. Monovalent P256 represents a safer form for in vivo applications

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

2017 ◽  
Vol 7 (04) ◽  
Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Lag Time ◽  
Oral Dosage ◽  
Lag Phase ◽  
Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

Sign in / Sign up

Export Citation Format

Share Document